Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies

• Main Authors: Rajbharan Yadav (Author), Siddharth Sukumaran (Author), Tanja S. Zabka (Author), Jinze Li (Author), Amy Oldendorp (Author), Gary Morrow (Author), Arthur Reyes (Author), Melissa Cheu (Author), Jessica Li (Author), Jeffrey J. Wallin (Author), Siao Tsai (Author), Laura Sun (Author), Peiyin Wang (Author), Diego Ellerman (Author), Christoph Spiess (Author), Andy Polson (Author), Eric G. Stefanich (Author), Amrita V. Kamath (Author), Meric A. Ovacik (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for pr...